<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865575</url>
  </required_header>
  <id_info>
    <org_study_id>NL55788.041.15</org_study_id>
    <nct_id>NCT04865575</nct_id>
  </id_info>
  <brief_title>Systems Pharmacology Approach to Uncontrolled Pediatric Asthma</brief_title>
  <official_title>Systems Pharmacology Approach to Uncontrolled Pediatric Asthma (SysPharmPediA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maribor, Maribor, Slovenia.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children's Hospital, University of Regensburg, Regensburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de La Laguna, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the Basque Country (UPV/EHU), San Sebastián, Spain.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Donostia, San Sebastián, Spain.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III, Madrid, Comunidad de Madrid, Spain.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Utrecht University, Utrecht, the Netherlands.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet, Stockholm, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Asthma is a heterogeneous respiratory disease and the most common chronic disease in&#xD;
      children. A small subset of children has continuous poor asthma control despite appropriate&#xD;
      adherence to asthma medication. There is a clinical need to identify these children as early&#xD;
      as possible to optimize treatment and/or to find therapeutic alternatives. Therefore, the&#xD;
      &quot;Systems Pharmacology approach to uncontrolled Pediatric Asthma&quot; (SysPharmPediA) study was&#xD;
      set up.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To establish a cohort of pediatric moderate-to-severe uncontrolled and controlled patients&#xD;
      with asthma in order to investigate pathophysiological mechanisms underlying uncontrolled&#xD;
      moderate-to-severe asthma in children on maintenance treatment, using a multi-omics systems&#xD;
      medicine approach.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      In this multicenter observational case-control study, moderate-to-severe asthmatic children&#xD;
      (n=145, age 6-17 years), were included in specialized hospitals in four European countries&#xD;
      (Netherlands, Germany, Spain and Slovenia). Recruited subjects were selected based on good&#xD;
      asthma control (controlled asthmatics, n=54) or poor asthma control / recurrent exacerbations&#xD;
      (uncontrolled asthmatics, n=91). Comprehensive details concerning demographics, current and&#xD;
      past patient/family history and clinical characteristics were collected. In addition,&#xD;
      systems-wide omics layers, including epi(genomics), transcriptomics, microbiome, proteomics&#xD;
      and metabolomics will be evaluated from multiple collected, relatively non-invasive, samples&#xD;
      of from the recruited individuals, such as: blood, feces, saliva, nasal swabs and exhaled&#xD;
      breath. Follow-up visits were performed 6 and 12 months after inclusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Saliva and stool microbiome</measure>
    <time_frame>Baseline</time_frame>
    <description>Differences in 16S rRNA microbial α- and ß- diversities between cases and controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exhaled breath metabolome</measure>
    <time_frame>Baseline</time_frame>
    <description>Differences in presence and levels of volatile organic compounds between cases and controls</description>
  </primary_outcome>
  <other_outcome>
    <measure>Age</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>Age in years</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>Female/Male</description>
  </other_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>kg/m2</description>
  </other_outcome>
  <other_outcome>
    <measure>Uncontrolled asthma</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>according to the Asthma Control Test (ACT) questionnaire (&lt;19 score) and frequent exacerbation within the past 12 months (&gt;n of exacerbation in the past 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Exacerbations</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>Exacerbation requiring OCS use, hospitalization or ER visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Spirometry</measure>
    <time_frame>Baseline</time_frame>
    <description>FEV1 (L, percent predicted value)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pediatric Asthma Quality of Life Questionnaire (PAQLQ)</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>Questionnaire including 23 questions in 3 domains (symptoms, activity limitation, emotional function) and a 7-point scale (7 = not bothered at all; 1 = extremely bothered)</description>
  </other_outcome>
  <other_outcome>
    <measure>Atopy</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>Questionnaire on history of allergic diseases</description>
  </other_outcome>
  <other_outcome>
    <measure>Current asthma medication intake</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>ICS: inhaled corticosteroids, LTRA: leukotriene antagonist, SABA: short-acting beta agonist, LABA: long-acting beta agonist, OCS: oral corticosteroids, Omalizumab, Mepolizumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Asthma severity</measure>
    <time_frame>Baseline (+ follow-up at 6 and 12 months after baseline inclusion)</time_frame>
    <description>Asthma Control Test (ACT)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">145</enrollment>
  <condition>Pediatric Asthma</condition>
  <condition>Uncontrolled Asthma</condition>
  <arm_group>
    <arm_group_label>controlled asthmatics</arm_group_label>
    <description>moderate-to-severe asthmatic children with good asthma control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uncontrolled asthmatics</arm_group_label>
    <description>moderate-to-severe asthmatic children with poor asthma control / recurrent exacerbations</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, feces, saliva, nasal swabs and exhaled breath.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Four tertiary care centers from four European countries (the Netherlands, Germany, Spain,&#xD;
        and Slovenia) recruited 145 asthmatic children and adolescents (6-17 years old). All&#xD;
        centers obtained approval from their local medical ethics committee (ethics committee of&#xD;
        University Regensburg, Germany (18-1034-101); Clinical Research Ethics Committee of the&#xD;
        Basque Country, Spain (PI2015075 (SO)); Medical Ethics Committee of the University Medical&#xD;
        Center Utrecht (UMC Utrecht), Utrecht, the Netherlands (NL55788.041.15); National Medical&#xD;
        Ethics Committee, Slovenia (0120-569/2017/4)) and written informed consents were collected&#xD;
        from the parents/caregivers and/or the recruited children when appropriate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Between 6-17 years of age&#xD;
&#xD;
          -  Doctor diagnosis of asthma&#xD;
&#xD;
        In addition to the general criteria, a case with uncontrolled asthma (case group A) should&#xD;
        meet:&#xD;
&#xD;
          -  Asthma treatment Global INitiative of Asthma (GINA) step 3 or higher&#xD;
&#xD;
             ≥ 1of the following criteria (based on the guideline 'Childhood Asthma' of the section&#xD;
             paediatric pulmonology of the Dutch Society of Paediatricians, 2007):&#xD;
&#xD;
          -  Frequent exacerbations requiring OCS use (≥1 in the past year) and/or&#xD;
&#xD;
          -  Severe exacerbations requiring hospitalization or ER visits in the past year and/or&#xD;
&#xD;
          -  ACQ/ACT scores indicating uncontrolled asthma&#xD;
&#xD;
        In addition to the general criteria, a case with an acute exacerbation (case group B)&#xD;
        should meet:&#xD;
&#xD;
          -  Asthma treatment Global INitiative of Asthma (GINA) step 2 or higher&#xD;
&#xD;
          -  Current severe asthma exacerbation requiring hospitalization&#xD;
&#xD;
        In addition to the general inclusion criteria, a control (controlled asthma) should meet&#xD;
        the following criteria:&#xD;
&#xD;
          -  Asthma treatment Global INitiative of Asthma (GINA) step 3 or higher&#xD;
&#xD;
          -  Lack of severe exacerbations requiring OCS use or hospitalizations or ER visits in the&#xD;
             past year&#xD;
&#xD;
          -  ACQ/ACT scores indicating well controlled asthma or few reported asthma symptoms&#xD;
             during asthma checks in the past year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent use of a course of antibiotics (&lt; 1 month). This will affect the microbiome&#xD;
             analyses.&#xD;
&#xD;
        A patient can be re-screened 1 month after the use of the antibiotic treatment has&#xD;
        finished.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utrecht University</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maribor</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Basque Country</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de La Laguna</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. dr. A.H. Maitland-van der Zee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Systems Pharmacology</keyword>
  <keyword>Omics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>In case other researchers are interested to work with data that is collected within SysPharmPediA; we kindly request to contact the PI of the study (Prof. dr. A.H. Maitland-van der Zee - a.h.maitland@amsterdamumc.nl)&#xD;
The PIs will refer to an up-to-list of planned publications, which includes ongoing and planned analysis work from SysPharmPediA partners and from those granted access to specific data, to determine potential duplication of work.&#xD;
To understand and draw sound scientific results those groups planning to work on SysPharmPediA data should engage with the SysPharmPediA members who have generated the data in question.&#xD;
A summary of the Data Analysis Plan (DAP) must be attached to the data access request form.&#xD;
If the analysis deviates substantially from the summary DAP or provides results which the SysPharmPediA group feel mis-represent the data, the SysPharmPediA group may raise an objection with the publication concerned.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

